Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Kogenate FS Supply To Reach 80% Of 2000 Factor VIII Levels By 2002

Executive Summary

Bayer expects Kogenate FS recombinant factor VIII supply in 2002 to be approximately 80% of levels in 2000, and to exceed previous quantities by 2003, Bayer board member Frank Morich, MD, told analysts.

You may also be interested in...



Bayer May Cut U.S. Sales Force After Cipro Generics Enter Market

Bayer is looking to make further cuts in its U.S. pharmaceutical division following entry of Cipro generics, Bayer Health Care Chairman Arthur Higgins said during an earnings conference Aug. 3

Bayer May Cut U.S. Sales Force After Cipro Generics Enter Market

Bayer is looking to make further cuts in its U.S. pharmaceutical division following entry of Cipro generics, Bayer Health Care Chairman Arthur Higgins said during an earnings conference Aug. 3

Wyeth To File Refacto AF Second Quarter; Will Launch End Supply Problems?

Wyeth plans to file its second-generation antihemophilic factor VIII product Refacto AF during the second quarter, Wyeth President-Global Pharmaceuticals Bernard Poussot said during a Jan. 28 analyst call

Related Content

UsernamePublicRestriction

Register

PS038362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel